Literature DB >> 8590304

Production of interferon-gamma by chicken T cells.

J W Lowenthal1, M R Digby, J J York.   

Abstract

In mammals, interferon (IFN)-alpha/beta (type I) is typically resistant to exposure to heat and low pH, whereas IFN-gamma (type II) is labile. Type I IFN has been described in birds; however, the existence of type II IFN has been questioned. We have generated cloned chicken T cell lines that produce high levels of IFN and have studied the physiochemical properties of this IFN activity to determine whether it represents the type I or type II IFN found in mammals. When incubated at 60 degrees C, the IFN activity present in the supernatants from these chicken T cells was found to be labile, two-thirds of the activity being lost within 1-2 minutes. Consistent with IFN-gamma activity, this heat-labile IFN was also sensitive to exposure to pH 2. The heat-resistant IFN lost activity at a much slower rate (half-life > 2 h at 60 degrees C) and was also resistant to exposure to pH 2, which is characteristic of IFN-alpha/beta. To confirm further the presence of IFN-gamma activity, these T cell supernatants were assayed for their ability to activate macrophages as measured by induction of nitrite production. Consistent with mammalian IFN-gamma, the nitrite-inducing activity was found to be heat labile, with over 90% of the activity lost within 5 minutes of heating. These results show that chicken T cells produce IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8590304     DOI: 10.1089/jir.1995.15.933

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  8 in total

1.  Infection with chicken anaemia virus impairs the generation of pathogen-specific cytotoxic T lymphocytes.

Authors:  Carrie J Markowski-Grimsrud; Karel A Schat
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

Review 2.  Recent advances in biology and immunobiology of Eimeria species and in diagnosis and control of infection with these coccidian parasites of poultry.

Authors:  P C Allen; R H Fetterer
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

3.  Immune responses to oral vaccination with Salmonella-delivered avian pathogenic Escherichia coli antigens and protective efficacy against colibacillosis.

Authors:  John Hwa Lee; Atul A Chaudhari; In Gyoung Oh; Seong Kug Eo; Sang-Youel Park; Chetan V Jawale
Journal:  Can J Vet Res       Date:  2015-07       Impact factor: 1.310

4.  Flagellin from recombinant attenuated Salmonella enterica serovar Typhimurium reveals a fundamental role in chicken innate immunity.

Authors:  Zhiming Pan; Qiuxia Cong; Shizhong Geng; Qiang Fang; Xilong Kang; Meng You; Xinan Jiao
Journal:  Clin Vaccine Immunol       Date:  2012-01-11

5.  The different expression of immune-related cytokine genes in response to velogenic and lentogenic Newcastle disease viruses infection in chicken peripheral blood.

Authors:  Wen-Quan Liu; Ming-Xing Tian; Yuan-Ping Wang; Yang Zhao; Nian-Li Zou; Fang-Fang Zhao; San-Jie Cao; Xin-Tian Wen; Ping Liu; Yong Huang
Journal:  Mol Biol Rep       Date:  2011-07-05       Impact factor: 2.316

6.  Effects of Chicken Interferon Gamma on Newcastle Disease Virus Vaccine Immunogenicity.

Authors:  Stivalis Cardenas-Garcia; Robert P Dunwoody; Valerie Marcano; Diego G Diel; Robert J Williams; Robert M Gogal; Corrie C Brown; Patti J Miller; Claudio L Afonso
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

7.  Protective efficacy and immune responses by homologous prime-booster immunizations of a novel inactivated Salmonella Gallinarum vaccine candidate.

Authors:  Gayeon Won; Atul A Chaudhari; John Hwa Lee
Journal:  Clin Exp Vaccine Res       Date:  2016-07-29

8.  IFN-γ establishes interferon-stimulated gene-mediated antiviral state against Newcastle disease virus in chicken fibroblasts.

Authors:  Xin Yang; Mehboob Arslan; Xingjian Liu; Haozhi Song; Mengtan Du; Yinü Li; Zhifang Zhang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2020-03-18       Impact factor: 3.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.